96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...
96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...
96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
sease and 30 colon cancer serum samples were included for additional<br />
specificity testing.<br />
Results. Based on the training study we could evaluate the top candidate<br />
biomarkers with the best values for sensitivity and specificity. A marker<br />
panel of DKK3 and ITIH5 detected breast cancer with a sensitivity of 46%<br />
(55/120). Specificity of the panel was sufficient with 83%, 100% and 93% in<br />
colon cancer samples, benign and healthy control samples, respectively.<br />
Control samples revealed unacceptable high methylation rates of SFRP1<br />
and SFRP5 in DNA extracted from colon cancer sera, whereas SFRP2<br />
and WIF1 showed a consi<strong>der</strong>able methylation frequency in sera from<br />
healthy controls.<br />
Conclusions. The current study suggests that cancer-specific methylation<br />
of ITIH5 and DKK3 in serum-<strong>der</strong>ived tumor-borne DNA might be<br />
valuable biomarkers for the early detection of breast cancer. In the second<br />
phase of this project we are currently validating ITIH5 and DKK3<br />
as reliable methylation biodiagnostic markers in an independent test set<br />
consisting of 160 breast cancer serum samples and 160 control samples.<br />
SG-145<br />
Slug and SOX9 in aggressive breast carcinoma<br />
V . Tischler1 , A . Noske1 , U . Zürrer-Härdi1 , F . Ingold1 , J .-P . Theurillat1 , H . Moch1 , Z .<br />
Varga1 , W . Guo2 1University Hospital Zurich, Institute of Surgical Pathology, Zürich, Switzerland,<br />
2Albert Einstein College of Medicine, Ruth L . and David S . Gottesman<br />
Institute for Stem Cell Biology and Regenerative Medicine, New York, United<br />
States<br />
Aims. Co-expression of the transcription factors Slug and Sox9 was recently<br />
used to determine mammary stem cell state. Our intention was<br />
to study the expression of Slug and Sox9 in primary breast cancer and<br />
to correlate it with clinicopathological parameters including overall survival.<br />
Methods. Formalin-fixed paraffin embedded tumor tissue of 306 patients<br />
with primary breast cancer [pT1 132 (43.1%), pT2 134 (43.8%), pT3 21<br />
(6.9%), pT4 19 (6.2%); pN0 92 (34.1%), pN1 136 (50.4%), pN2 22 (8.1%), pN3<br />
20 (7.4%); G1 41 (13.4%), G2 144 (47.1%), G3 121 (39.5%)] were assembled<br />
on a tissue microarray (TMA). Mean follow-up was 40 months (range<br />
4–324 months). Immunohistochemical Slug and Sox9 expression was semi-quantitatively<br />
evaluated. The median value was used as cut-off point<br />
for dichotomization into “low Slug”/”high Slug” and “low Sox9”/”high<br />
Sox9” expressing groups.<br />
Results. Slug and Sox9 expression was identified in the tumor cell nuclei.<br />
High Slug expression was found in 41% of the cases (126/306) and high<br />
Sox9 expression in 74% (226/306). High expression of both Slug and Sox9<br />
was found in 92/306 (30.1%). Co-expression of Slug and Sox9 significantly<br />
correlated with higher tumor grade (p